The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes

B. Zhitomirsky, Y. Assaraf
{"title":"The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes","authors":"B. Zhitomirsky, Y. Assaraf","doi":"10.14800/CCM.807","DOIUrl":null,"url":null,"abstract":"Hydrophobic weak base chemotherapeutics are known to markedly accumulate in lysosomes via a mechanism based on protonation and entrapment known as lysosomal drug sequestration. We have recently shown that lysosomal compartmentalization of these anticancer drugs can prevent them from exerting their cytotoxic activity by abolishing accessibility to their target sites, resulting in multidrug resistance. Consistently, we as well as others have recently demonstrated that lysosomal sequestration of the receptor tyrosine kinase inhibitor sunitinib is a determinant of intrinsic resistance in human cancer cells. We specifically found that the number of sunitinib sequestering lysosomes tightly correlated with intrinsic resistance to sunitinib in various naive tumor cell lines of distinct tissue lineage. We further demonstrated that lysosomal accumulation of several hydrophobic weak base drugs triggers activation of lysosomal biogenesis via translocation of the master regulator TFEB from the cytoplasm to the nucleus. This resulted in activation of the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network. This drug-induced activation of lysosomal biogenesis brought about a marked increase in lysosome number per cell. Here we demonstrate the role of alterations in the cytoplasm-to-lysosome pH gradient in lysosomal sequestration of anticancer drugs. We specifically show that MCF-7 breast cancer cells which display a markedly diminished cytoplasm-to-lysosome pH gradient due to both decreased lysosomal acidification and acidification of cytoplasmic pH, are devoid of hydrophobic weak base drug sequestration in lysosomes. The latter finding was of particular significance as MCF-7 cells were found to harbor a relatively high number of lysosomes per cell. We further show that disruption of lysosomal acidification using bafilomycin A1, an inhibitor of vacuolar H + ATPase (V-ATPase), prevents lysosomal drug sequestration when performed prior to hydrophobic weak base drug exposure. Moreover, such lysosomal alkalinization performed after lysosomal drug sequestration, results in massive drug release from lysosomes into the cytoplasm, hence restoring drug accessibility to the cellular target site. These findings have significant implications for the overcoming of lysosome-dependent cancer chemoresistance.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer cell & microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/CCM.807","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Hydrophobic weak base chemotherapeutics are known to markedly accumulate in lysosomes via a mechanism based on protonation and entrapment known as lysosomal drug sequestration. We have recently shown that lysosomal compartmentalization of these anticancer drugs can prevent them from exerting their cytotoxic activity by abolishing accessibility to their target sites, resulting in multidrug resistance. Consistently, we as well as others have recently demonstrated that lysosomal sequestration of the receptor tyrosine kinase inhibitor sunitinib is a determinant of intrinsic resistance in human cancer cells. We specifically found that the number of sunitinib sequestering lysosomes tightly correlated with intrinsic resistance to sunitinib in various naive tumor cell lines of distinct tissue lineage. We further demonstrated that lysosomal accumulation of several hydrophobic weak base drugs triggers activation of lysosomal biogenesis via translocation of the master regulator TFEB from the cytoplasm to the nucleus. This resulted in activation of the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network. This drug-induced activation of lysosomal biogenesis brought about a marked increase in lysosome number per cell. Here we demonstrate the role of alterations in the cytoplasm-to-lysosome pH gradient in lysosomal sequestration of anticancer drugs. We specifically show that MCF-7 breast cancer cells which display a markedly diminished cytoplasm-to-lysosome pH gradient due to both decreased lysosomal acidification and acidification of cytoplasmic pH, are devoid of hydrophobic weak base drug sequestration in lysosomes. The latter finding was of particular significance as MCF-7 cells were found to harbor a relatively high number of lysosomes per cell. We further show that disruption of lysosomal acidification using bafilomycin A1, an inhibitor of vacuolar H + ATPase (V-ATPase), prevents lysosomal drug sequestration when performed prior to hydrophobic weak base drug exposure. Moreover, such lysosomal alkalinization performed after lysosomal drug sequestration, results in massive drug release from lysosomes into the cytoplasm, hence restoring drug accessibility to the cellular target site. These findings have significant implications for the overcoming of lysosome-dependent cancer chemoresistance.
细胞质-溶酶体pH梯度在溶酶体疏水弱碱药物隔离中的作用
疏水弱碱化疗药物通过质子化和被称为溶酶体药物隔离的包裹机制在溶酶体中显著积累。我们最近的研究表明,这些抗癌药物的溶酶体区室化可以通过破坏其靶点的可及性来阻止它们发挥其细胞毒性活性,从而导致多药耐药。一致地,我们以及其他人最近已经证明,受体酪氨酸激酶抑制剂舒尼替尼的溶酶体隔离是人类癌细胞内在抗性的决定因素。我们特别发现,在不同组织谱系的各种原始肿瘤细胞系中,舒尼替尼隔离溶酶体的数量与对舒尼替尼的内在耐药性密切相关。我们进一步证明,溶酶体积累的几种疏水弱碱基药物通过将主调节因子TFEB从细胞质转运到细胞核,触发了溶酶体生物发生的激活。这导致协调溶酶体表达和调控(CLEAR)基因网络的激活。这种药物诱导的溶酶体生物发生的激活使每个细胞的溶酶体数量显著增加。在这里,我们证明了细胞质-溶酶体pH梯度的改变在溶酶体隔离抗癌药物中的作用。我们特别表明,MCF-7乳腺癌细胞由于溶酶体酸化和细胞质pH酸化的降低而显示出细胞质到溶酶体的pH梯度明显降低,溶酶体中缺乏疏水弱碱药物隔离。后一个发现是特别重要的,因为MCF-7细胞被发现每个细胞含有相对较多的溶酶体。我们进一步表明,使用巴菲霉素A1(一种空泡H + atp酶(v - atp酶)抑制剂)破坏溶酶体酸化,在疏水弱碱药物暴露之前阻止溶酶体药物隔离。此外,溶酶体药物隔离后进行的溶酶体碱化导致溶酶体释放大量药物进入细胞质,从而恢复药物对细胞靶部位的可及性。这些发现对克服溶酶体依赖性癌症化学耐药具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信